

CITATION REPORT

List of articles citing

The selective muscarinic M1 agonist AF102B decreases levels of total A β in cerebrospinal fluid of patients with Alzheimer's disease

DOI: 10.1002/1531-8249(200012)48:63.0.co;2-s
Annals of Neurology, 2000, 48, 913-918.

Source: <https://exaly.com/paper-pdf/31291601/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
142	Use of muscarinic agonists in the treatment of Sjögren's syndrome. 2001 , 101, 249-63		83
141	Selective antibody-induced cholinergic cell and synapse loss produce sustained hippocampal and cortical hypometabolism with correlated cognitive deficits. 2001 , 170, 36-47		36
140	Reduction of cortical amyloid beta levels in guinea pig brain after systemic administration of physostigmine. 2001 , 310, 21-4		34
139	Incorporating biomarkers into clinical drug trials in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2001 , 3, 287-292	4.3	23
138	Evaluating CNS Biomarkers for Alzheimer's Disease. 265-273		
137	Alzheimer disease therapeutics. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001 , 60, 923-8	3.1	33
136	Current Awareness. 2001 , 16, 341-348		
135	Biological markers and the treatment of Alzheimer's disease. 2001 , 17, 119-25		14
134	Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. 2001 , 905, 220-3		66
133	SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. 2001 , 431, 189-200		61
132	Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease. 2001 , 1, 194-206		18
131	Notch1 and amyloid precursor protein are competitive substrates for presenilin1-dependent gamma-secretase cleavage. 2001 , 276, 30018-23		63
130	Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. 2002 , 14, 156-60		23
129	Cholinergic agonists and the treatment of Alzheimer's disease. 2002 , 2, 353-8		29
128	Review of the Pharmacological Properties and Clinical Usefulness of Muscarinic Agonists for Xerostomia in Patients with Sjögren's Syndrome. 2002 , 22, 67-73		11
127	Biomarkers in Psychotropic Drug Development. 2002 , 10, 678-686		5
126	Biological Research on Dementias. 287-322		

125	. 2002 ,	6
124	Implications of amyloid precursor protein and subsequent beta-amyloid production to the pharmacotherapy of Alzheimer's disease. 2002 , 22, 1547-63	8
123	Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. 2002 , 951, 135-40	40
122	Development of CDD-0102 as a selective M1 agonist for the treatment of Alzheimer's disease. 2002 , 57, 200-213	10
121	The effect of scopolamine in older rabbits tested in the 750 ms delay eyeblink classical conditioning procedure. 2002 , 37, 103-13	4
120	AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. 2002 , 19, 145-53	67
119	The utility of muscarinic agonists in the treatment of Alzheimer's disease. 2002 , 19, 187-93	32
118	Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice. 2002 , 15, 498-506	22
117	M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. 2003 , 20, 349-56	119
116	Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. <i>Annals of Neurology</i> , 2003 , 54, 235-8	9.4 186
115	Chronically mad as a hatter: anticholinergics and Alzheimer's disease pathology. <i>Annals of Neurology</i> , 2003 , 54, 144-6	9.4 3
114	Clinical pharmacology of anti-Alzheimer drugs. 2003 , 17, 659-72	15
113	Clinically tested drugs for Alzheimer's disease. 2003 , 12, 1143-51	20
112	Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. 2003 , 43, 545-84	717
111	Protective effect of the heparin-derived oligosaccharide C3, on AF64A-induced cholinergic lesion in rats. 2003 , 24, 481-90	20
110	Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. 2003 , 10, 1-6	75
109	Treatment of dementia with neurotransmission modulation. 2003 , 12, 1633-54	27
108	Drugs that target muscarinic cholinergic receptors. 2004 , 37-48	5

107	Cortical Lewy body disease. 2004 , 75, 175-8	14
106	Neuroprotective strategies in Alzheimer's disease. 2004 , 1, 117-27	55
105	A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. 2004 , 113, 1456-64	438
104	Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. 2005 , 28, 126-32	181
103	Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling. 2005 , 30, 895-908	130
102	The role of β amyloid in Alzheimer's disease. 2005 , 452-458	
101	Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. 2005 , 11, 3353-61	87
100	Neurochemistry of severe dementia. 2005 , 15, 105-123	1
99	Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. 2005 , 48, 913-22	882
98	Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. 2005 , 48, 4444-56	76
97	The non-amyloidogenic pathway: structure and function of alpha-secretases. 2005 , 38, 105-27	133
96	Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?. 2006 , 2, 118-25	40
95	Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. 2006 , 24, 149-56	56
94	In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors. 2006 , 27, 413-22	71
93	The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. 2006 , 113, 1625-44	392
92	Alpha-secretase activation--an approach to Alzheimer's disease therapy. 2006 , 3, 255-61	49
91	The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. 2006 , 20, 512-4	94
90	M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update. 2007 , 4, 577-80	41

89	Alpha-secretase as a therapeutic target. 2007 , 4, 412-7		85
88	Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. <i>Neurology</i> , 2007 , 68, 666-9	6.5	201
87	Pharmacological Mechanisms in Alzheimer's Therapeutics. 2007 ,		1
86	M1 Muscarinic Agonists: A Comprehensive Therapy Against Major Hallmarks of Alzheimer's Disease. 2007 , 50-63		
85	Effects of beta-amyloid protein on M1 and M2 subtypes of muscarinic acetylcholine receptors in the medial septum-diagonal band complex of the rat: relationship with cholinergic, GABAergic, and calcium-binding protein perikarya. 2007 , 113, 637-51		6
84	A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. 2008 , 23, 155-60		57
83	Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. <i>Neurotherapeutics</i> , 2008 , 5, 433-42	6.4	114
82	Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. <i>Neurotherapeutics</i> , 2008 , 5, 381-90	6.4	17
81	Effects of beta-amyloid peptide on the density of M2 muscarinic acetylcholine receptor protein in the hippocampus of the rat: relationship with GABA-, calcium-binding protein and somatostatin-containing cells. 2008 , 34, 506-22		11
80	M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors. 2008 , 5, 237-40		65
79	Advances in Alzheimer's and Parkinson's Disease. 2008 ,		
78	Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. 2008 , 58, 42-51		455
77	A closer look at alpha-secretase. 2008 , 5, 179-86		95
76	The clinical significance of plasmatic amyloid A{beta}-40 peptide levels in Alzheimer's disease patients treated with galantamine. 2008 , 23, 286-90		1
75	M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. 2009 , 6, 112-7		54
74	A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. 2009 , 29, 14271-86		187
73	Monitoring the amyloid beta-peptide in vivo--caveat emptor. 2009 , 14, 241-51		9
72	Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. 2009 , 26, 537-55		67

71	Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein. 2009 , 21, 386-406	35
70	Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. 2009 , 29, 4442-60	148
69	Current therapeutic targets for the treatment of Alzheimer's disease. 2010 , 10, 711-28	83
68	Alzheimer's disease. 2010 , 362, 329-44	3463
67	Alzheimer's disease: clinical trials and drug development. 2010 , 9, 702-16	836
66	Viable mouse gene ablations that robustly alter brain A β levels are rare. 2010 , 11, 143	10
65	Amyloid- β as a modulator of synaptic plasticity. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 741-63	4.3 170
64	Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. 2010 , 30, 4190-6	95
63	Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. 2010 , 7, 40-55	95
62	Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. 2010 , 6, 1345-54	52
61	Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease. 2010 , 40, 63-70	29
60	Biomarkers in Alzheimer's disease drug development. 2011 , 7, e13-44	87
59	ADAM10: potential β molecular scissors for the treatment of Alzheimer's disease. 2011 , 6, 1-4	
58	β secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential. 2011 , 116, 10-21	131
57	Targets for AD treatment: conflicting messages from β secretase inhibitors. 2011 , 117, 359-74	49
56	The role of G protein-coupled receptors in the pathology of Alzheimer's disease. 2011 , 12, 73-87	198
55	Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. 2011 , 122, 49-60	62
54	Opposing synaptic regulation of amyloid- β metabolism by NMDA receptors in vivo. 2011 , 31, 11328-37	47

53	Serotonin signaling is associated with lower amyloid- β levels and plaques in transgenic mice and humans. 2011 , 108, 14968-73		218
52	Synapses, NMDA receptor activity and neuronal A β production in Alzheimer's disease. <i>Reviews in the Neurosciences</i> , 2011 , 22, 285-94	4-7	53
51	Alpha-secretase cleavage of the amyloid precursor protein: proteolysis regulated by signaling pathways and protein trafficking. 2012 , 9, 165-77		53
50	Role of APP and A β in synaptic physiology. 2012 , 9, 217-26		34
49	Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. <i>Journal of Alzheimer's Disease</i> , 2012 , 32, 793-887	4-3	44
48	Attenuation of scopolamine-induced cognitive dysfunction by obovatol. 2012 , 35, 1279-86		20
47	Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. 2012 , 120 Suppl 1, 22-33		94
46	Alzheimer culprits: cellular crossroads and interplay. 2012 , 24, 1831-40		56
45	Extracellular Amyloid- β Protein Dynamics in Alzheimer's Disease. 2013 , 163-178		2
44	Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid β (1-42). <i>Neuropharmacology</i> , 2013 , 67, 272-83	5-5	24
43	Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease. 2013 , 230, 279-89		26
42	Rapid β amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013 , 72, 272-85	3-1	58
41	Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia. <i>Biomarkers in Medicine</i> , 2014 , 8, 29-49	2-3	11
40	Therapeutics of Alzheimer's disease: Past, present and future. <i>Neuropharmacology</i> , 2014 , 76 Pt A, 27-50	5-5	477
39	Deep Brain Stimulation of the Nucleus Basalis of Meynert in Early Stage of Alzheimer's Dementia. <i>Brain Stimulation</i> , 2015 , 8, 838-9	5-1	45
38	Synthesis and biological evaluation of isoxazoline derivatives as potent M μ muscarinic acetylcholine receptor agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015 , 25, 1546-51	2-9	5
37	Acute Effects of Muscarinic M1 Receptor Modulation on APP Metabolism and Amyloid- β Levels in vivo: A Microdialysis Study. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 971-82	4-3	11
36	Brain aerobic glycolysis functions and Alzheimer's disease. <i>Clinical and Translational Imaging</i> , 2015 , 3, 27-37	2	49

35	Transcranial Direct Current Stimulation Against Sudden Unexpected Death in Epilepsy: Press That Button Again, Please. <i>Brain Stimulation</i> , 2015 , 8, 839-40	5.1	4
34	AChE and the amyloid precursor protein (APP) - Cross-talk in Alzheimer's disease. <i>Chemico-Biological Interactions</i> , 2016 , 259, 301-306	5	35
33	Therapeutics of Neurotransmitters in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 1049-1069	4.1	97
32	The Neurotoxic Role of Extracellular Tau Protein. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	34
31	Deep Brain Stimulation: A Potential Treatment for Dementia in Alzheimer's Disease (AD) and Parkinson's Disease Dementia (PDD). <i>Frontiers in Neuroscience</i> , 2018 , 12, 360	5.1	14
30	Targeting the Iron-Response Elements of the mRNAs for the Alzheimer's Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	9
29	Future Directions in Deep Brain Stimulation. 2019 , 229-253		1
28	G protein-coupled receptors in neurodegenerative diseases. 2020 , 335-365		
27	Drug repositioning and repurposing for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2020 , 16, 661-673	15	44
26	Effect of escitalopram on A β levels and plaque load in an Alzheimer mouse model. <i>Neurology</i> , 2020 , 95, e2666-e2674	6.5	9
25	Iron-responsive-like elements and neurodegenerative ferroptosis. <i>Learning and Memory</i> , 2020 , 27, 395-413	13	7
24	GeNeDis 2018. <i>Advances in Experimental Medicine and Biology</i> , 2020 ,	3.6	
23	Amyloid- β /tau, and the cholinergic system in Alzheimer's disease: seeking direction in a tangle of clues. <i>Reviews in the Neurosciences</i> , 2020 , 31, 391-413	4.7	26
22	A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy. <i>Medicinal Research Reviews</i> , 2021 , 41, 2689-2745	14.4	3
21	Omega 3 PUFA. 2021 , 65-82		
20	Neuropharmacology of Cevimeline and Muscarinic Drugs-Focus on Cognition and Neurodegeneration. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
19	Alzheimer's Disease Therapeutic Approaches. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1195, 105-116	3.6	12
18	Synaptic Transmission Dynamically Modulates Interstitial Fluid Amyloid- β Levels. <i>Research and Perspectives in Alzheimer's Disease</i> , 2008 , 133-143		1

17	Impact of muscarinic agonists for successful therapy of Alzheimer's disease. <i>Journal of Neural Transmission Supplementum</i> , 2002 , 189-202		8
16	M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?. <i>Advances in Pharmacology</i> , 2020 , 88, 277-310	5.7	11
15	Pharmacological properties of TV3326, a cholinesterase and brain selective monoamine oxidase inhibitor for the treatment of dementia co-morbid with depression. 2005 , 279-282		1
14	Potential Enzymatic Targets in Alzheimer's: A Comprehensive Review. <i>Current Drug Targets</i> , 2019 , 20, 316-339	3	17
13	Die Alzheimer-Krankheit: Molekulare Grundlagen und Therapieansätze. 2004 , 148-179		
12	Beta-amyloids, tau hyperphosphorylation and cognition are beneficially affected by M1 muscarinic agonists. 2004 , 345-351		
11	βAmyloid Therapeutic Strategies for Alzheimer's Disease.		0
10	Up-regulation of the βSecretase Pathway. 2008 , 369-374		1
9	Cortical Cholinergic Lesion Causes AβDeposition: Cholinergic-Amyloid Fusion Hypothesis. 2008 , 411-427		
8	Cortical Cholinergic Deafferentation Induces AβDeposition. 2005 , 143-180		
7	Neuroprotective strategies in Alzheimer's disease. <i>Neurotherapeutics</i> , 2004 , 1, 117-127	6.4	
6	A M1 muscarinic acetylcholine receptor positive allosteric modulator improves pathology and cognitive deficits in female APP ^{swe} /PSEN1 ^{E9} mice. <i>British Journal of Pharmacology</i> , 2021 ,	8.6	3
5	Reimagining cholinergic therapy for Alzheimer's disease.. <i>Brain</i> , 2022 ,	11.2	4
4	Understanding How Physical Exercise Improves Alzheimer's Disease: Cholinergic and Monoaminergic Systems. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14,	5.3	0
3	A Novel Multifunctional 5,6-Dimethoxy-Indanone-Chalcone-Carbamate Hybrids Alleviates Cognitive Decline in Alzheimer's Disease by Dual Inhibition of Acetylcholinesterase and Inflammation. <i>Frontiers in Aging Neuroscience</i> , 14,	5.3	0
2	Application of Marine Natural Products against Alzheimer's Disease: Past, Present and Future. 2023 , 21, 43		0
1	The Contribution of Transgenic Models to the Understanding of Alzheimer's Disease Progression and Therapeutic Development. 2011 , 1-14		0